Yousif Capital Management LLC Sells 22,586 Shares of Ralliant Corporation $RAL

Yousif Capital Management LLC lessened its position in shares of Ralliant Corporation (NYSE:RAL - Free Report) by 38.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,685 shares of the company's stock after selling 22,586 shares during the period. Yousif Capital Management LLC's holdings in Ralliant were worth $1,561,000 as of its most recent filing with the Securities and Exchange Commission.A number of other hedge funds have also added to or reduced their stakes in the company. Farmers & Merchants Investments Inc. acquired a new position in Ralliant during the second quarter valued at approximately $662,000. GAMMA Investing LLC acquired a new position in shares of Ralliant during the 2nd quarter worth $56,000. Alpha Omega Wealth Management LLC acquired a new position in shares of Ralliant during the 2nd quarter worth $213,000. Public Employees Retirement System of Ohio bought a new stake in shares of Ralliant during the 2nd quarter worth $1,799,000. Finally, TD Private Client Wealth LLC acquired a new stake in Ralliant in the second quarter valued at about $284,000. Ralliant Price PerformanceNYSE:RAL opened at $51.27 on Tuesday. Ralliant Corporation has a one year low of $40.70 and a one year high of $55.08. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39. The firm has a market cap of $5.78 billion and a P/E ratio of 40.37. The stock's 50 day simple moving average is $47.84. Ralliant (NYSE:RAL - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.02. The business had revenue of $529.10 million for the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS. Ralliant Announces DividendThe business also recently announced a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a yield of 0.4%. Ralliant's payout ratio is presently 15.75%. Wall Street Analysts Forecast GrowthSeveral brokerages have commented on RAL. Royal Bank Of Canada boosted their target price on Ralliant from $45.00 to $52.00 and gave the stock a "sector perform" rating in a research note on Friday, November 7th. Morgan Stanley assumed coverage on shares of Ralliant in a report on Tuesday, September 2nd. They set an "overweight" rating and a $55.00 price target on the stock. Oppenheimer increased their price objective on shares of Ralliant from $55.00 to $60.00 and gave the company an "outperform" rating in a research note on Monday, December 15th. Citigroup upgraded shares of Ralliant from a "neutral" rating to a "buy" rating and raised their target price for the company from $53.00 to $61.00 in a research report on Monday, December 8th. Finally, Truist Financial assumed coverage on shares of Ralliant in a research note on Friday, December 12th. They set a "buy" rating and a $62.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $57.89.View Our Latest Stock Analysis on RalliantAbout Ralliant (Free Report)Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure. The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.Recommended StoriesFive stocks we like better than RalliantBombshell Exposé on China StrikesWall Street Stockpicker Names #1 Stock of 2026ALERT: Drop these 5 stocks before January 2026!Chilling warning from legendary investorTrump’s new AI budget just passed — one stock could soarThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Ralliant Right Now?Before you consider Ralliant, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ralliant wasn't on the list.While Ralliant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here